Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced that it has administered doses to the first participants in a Phase 1/2a clinical trial for ARO-INHBE.

AstraZeneca's Tagrisso (osimertinib) has received approval from the European Union (EU) for treating adult individuals with locally advanced, unresectable NSCLC.

Epirium Bio has received FDA approval for its Investigational New Drug Application for MF-300. Additionally, Alex Casdin has been appointed as the new CEO.

CStone has submitted a clinical trial application in Australia for CS2009, a novel trispecific antibody targeting PD-1, VEGF, and CTLA-4.

This approval allows the company to commence its First-In-Human (FIH) Phase 1 therapeutic clinical trial of 177Lu-labelled RAD 202 aimed at treating HER2-expressing solid tumors.

The FDA has authorized Zepbound® (tirzepatide) as the first and sole prescription treatment for moderate to severe obstructive sleep apnea in obese adults.

The FDA has authorized Alhemo® injection for once-daily use to prevent or lessen bleeding episodes in adults and children aged 12 and up who have hemophilia A or B with inhibitors.

The U.S. FDA has approved the use of Pfizer's BRAFTOVI® combination therapy as a first-line treatment for metastatic colorectal cancer with BRAF V600E mutations.

Vertex has received US FDA approval for ALYFTREK™, a new once-daily CFTR modulator aimed at treating cystic fibrosis.

Marengo has dosed its initial patient in the Phase 2 clinical trial of Invikafusp Alfa (STAR0602) targeting PD-1 resistant tumors and is extending the study to Europe.

JCR Pharmaceuticals launches Phase III trial for JR-142 in Japan, a long-lasting growth hormone treatment.

Merck signs exclusive global licensing deal for LM-299, a candidate bispecific antibody targeting PD-1 and VEGF.